基底细胞癌新药Sonidegib的合成工艺优化  

Progress Improvement on Synthesis of Basal-cell Carcinoma Drug Sonidegib

作　　者：郇伟伟[1] 程超[2] 刘力[1] 李蕾 李洁[1,3] HUAN Wei-wei;CHENG Chao;LIU Li;LI Lei;LI Jie(Zhejiang Provincial Key Laboratory of Chemical Utilization of Forestry Biomass,Zhejiang A ＆ F University,Lin＇an 311300,China;Department of Nuclear Medicine,Changhai Hospital of Second Military Medical University,Shanghai 200433,China;Zhejiang Provincial Collaborative Innovation Center of Agricultural Biological Resources Biochemical Manufacturing,Hangzhou 310023,China)

机构地区：[1]浙江农林大学浙江省林业生物质化学利用重点实验室,浙江临安311300 [2]第二军医大学附属上海长海医院核医学科,上海200433 [3]浙江省农业生物资源生化制造协同创新中心,浙江杭州310023

出　　处：《合成化学》2018年第10期783-786,共4页Chinese Journal of Synthetic Chemistry

基　　金：浙江省基础公益研究计划项目(LGN18B010001);浙江农林大学人才启动基金资助项目(2034020059);浙江省农业生物资源生化制造协同创新中心开放基金资助项目(2016KF0005)

摘　　要：以2-氯-5-硝基吡啶为起始原料,经氢化、偶联和酰胺缩合反应合成Sonidegib,总收率71.4%,其结构经~1H NMR和MS(ESI)确证。The basal-cell carcinoma drug, Sonidegib, with total yield of 71.4% , was synthesized by hydrogenation, coupling and amide condensation reaction using 2-chloro-5-nitropyrdine as starting material. The structure was confirmed by ′H NMR and MS（ESI）.

关 键 词：细胞癌 Sonidegib 药物合成 工艺优化 

分 类 号：R914.5[医药卫生—药物化学]